Clinical Trials Browser

Phase 1 × Afatinib × 90 days × Clear all

NCT06302621 2026-01-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Phase 1 Completed

Head and Neck Neoplasms